Drugs / DEPATUXIZUMAB
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01472003 | Oct 2011 → Dec 2012 | cancer | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT01406119 | Oct 2011 → Jan 2017 | cancer | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT01255657 | Nov 2010 → Nov 2012 | cancer | AbbVie | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT02213289 | Jan 2015 → Feb 2020 | adenocarcinoma | University of Chicago | Completed | Met primary |
Press releases naming this drug 1 release
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DEPATUXIZUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707294 ↗ |
| Known as | ABT-806 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01472003 ↗ |
| Known as | Anti-egfr mab abt-806 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707294 ↗ |
| Known as | Anti-egfr moab abt-806 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707294 ↗ |
| Modality | Monoclonal antibody | “Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody” PMID 25761639 ↗ Oct 2015 |
| Route | Intravenous | “following intravenous infusion of ABT-806” PMID 25761639 ↗ Oct 2015 |
| Target | EGFR | “specific for a unique epitope of human epidermal growth factor receptor (EGFR)” PMID 25761639 ↗ Oct 2015 |